Sagimet Biosciences announced positive topline results from its FASCINATE-2 Phase 2b clinical trial of denifanstat versus placebo in biopsy-confirmed non-alcoholic steatohepatitis (NASH) patients with stage 2 or stage 3 fibrosis (F2/F3) at week 52. Denifanstat, an oral, selective FASN inhibitor, achieved statistically significant results on primary and multiple secondary endpoints.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.